Management benigner und prämaligner Veränderungen der Vulva und der Zervix

Mit dem in Deutschland seit 1. Januar 2020 geltenden, organisierten Zervixkarzinomscreening-Programm rücken Diagnose und Therapie von Veränderungen im Bereich der Vulva und der Cervix uteri in einen neuen Fokus. Der folgende Artikel liefert einen Überblick über die diagnostischen Möglichkeiten, aber auch die aktuell empfohlenen therapeutischen Maßnahmen bei typischen benignen und prämalignen Veränderungen der Vulva und der Cervix uteri.

Schlüsselwörter

Zervixdysplasie - Vulvadysplasie - humane Papillomaviren - Lichen sclerosus - CIN - Adenocarcinoma in situ - AIS

• Literatur

• 1 Quaas J, Reich O, Kuppers V. Explanation and Use of the Rio 2011 Colposcopy Nomenclature of the IFCPC (International Federation for Cervical Pathology and Colposcopy): Comments on the general colposcopic assessment of the uterine cervix: adequate/inadequate; squamocolumnar junction; transformation zone. Geburtshilfe Frauenheilkd 2014; 74: 1090-1092
• 2 Küppers V. Klinisches Bild, Prognose und Verlauf bei Infektionen mit HPV. Gynäkologe 2017; 50: 665-674
• 3 Chesson HW, Dunne EF, Hariri S. et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014; 41: 660-664
• 4 Buysse L, Klug S. Humane Papillomviren. Gynäkologe 2017; 50: 660-664
• 5 Smith JS, Lindsay L, Hoots B. et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-632
• 6 Einstein MH, Schiller JT, Viscidi RP. et al. Clinicianʼs guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9: 347-356
• 7 Schreckenberger C, Kaufmann A. Impfung gegen humane Papillomviren nach Zervixdysplasie und Genitalwarzen. Gynäkologe 2017; 50: 687-694
• 8 Rieck T, Feig M, Siedler A. et al. Aktuelles aus der KV-Impfsurveillance – Impfquoten ausgewählter Schutzimpfungen in Deutschland. In: Robert Koch-Institut, Epidemiologie und Gesundheitsberichterstattung; 2018
• 9 Robert Koch-Institut. Epidemiologisches Bulletin 34/2018. Berlin: RKI; 2018
• 10 Kirtschig G. Lichen Sclerosus-Presentation, Diagnosis and Management. Dtsch Arztebl Int 2016; 113: 337-343
• 11 Higgins CA, Cruickshank ME. A population-based case-control study of aetiological factors associated with vulval lichen sclerosus. J Obstet Gynaecol 2012; 32: 271-275
• 12 Terlou A, Santegoets LA, van der Meijden WI. et al. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155. J Invest Dermatol 2012; 132: 658-666
• 13 Sander CS, Ali I, Dean D. et al. Oxidative stress is implicated in the pathogenesis of lichen sclerosus. Br J Dermatol 2004; 151: 627-635
• 14 Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: A prospective cohort study of 507 women. JAMA Dermatol 2015; 151: 1061-1067
• 15 Kirtschig G, Becker K, Gunthert A. et al. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus. J Eur Acad Dermatol Venereol 2015; 29: e1-e43
• 16 Renner SK, Beckmann MW, Abel P. et al. Benigne Veränderungen der Vulva. Frauenheilk up2date 2018; 12: 343-355
• 17 Schnürch H, Ackermann S, Alt C. et al. Diagnosis, therapy and follow-up care of vulvar cancer and its precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015. Geburtshilfe Frauenheilkd 2016; 76: 1035-1049
• 18 de Witte CJ, van de Sande AJ, van Beekhuizen HJ. et al. Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review. Gynecol Oncol 2015; 139: 377-384
• 19 Schmidmayr M, Kleinsorge F, Schnelzer A. et al. Therapie der Infektion mit humanen Papillomviren. Gynäkologe 2017; 50: 675-681
• 20 Helm CW, Lorenz DJ, Meyer NJ. et al. Retinoids for preventing the progression of cervical intra-epithelial neoplasia. Cochrane Database Syst Rev 2013; (06) CD003296
• 21 Scheinfeld N. Update on the treatment of genital warts. Dermatology Online J 2013; 19: 18559
• 22 Steben M, LaBelle D. Genital warts: Canadiansʼ perception, health-related behaviors, and treatment preferences. J Low Genit Tract Dis 2012; 16: 409-415
• 23 Bonnez W, Elswick RK, Bailey-Farchione A. et al. Efficacy and safety of 0.5 % podofilox solution in the treatment and suppression of anogenital warts. Am J Med 1994; 96: 420-425
• 24 Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res 2017; 27: 59-73
• 25 Stephenson RD, Denehy TR. Rapid spontaneous regression of acute-onset vulvar intraepithelial neoplasia 3 in young women: a case series. J Low Genit Tract Dis 2012; 16: 56-58
• 26 van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005; 97: 645-651
• 27 Hampl M, Sarajuuri H, Wentzensen N. et al. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006; 108: 1361-1368
• 28 Joura EA, Garland SM, Paavonen J. et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012; 344: e1401
• 29 Eva LJ. Screening and follow up of vulval skin disorders. Best Pract Res Clin Obstet Gynaecol 2012; 26: 175-188
• 30 van den Einden LC, de Hullu JA, Massuger LF. et al. Interobserver variability and the effect of education in the histopathological diagnosis of differentiated vulvar intraepithelial neoplasia. Mod Pathol 2013; 26: 874-880
• 31 Pepas L, Kaushik S, Nordin A. et al. Medical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev 2015; (08) CD007924
• 32 Delport ES. Extramammary Pagetʼs disease of the vulva: An annotated review of the current literature. Australas J Dermatol 2013; 54: 9-21
• 33 Emons G, Steiner E, Vordermark D. et al. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. Geburtshilfe Frauenheilkd 2018; 78: 1089-1109
• 34 Sasaki LMP, Andrade KRC, Figueiredo A. et al. Factors associated with malignancy in hysteroscopically resected endometrial polyps: A systematic review and meta-Analysis. J Minim Invasive Gynecol 2018; 25: 777-785
• 35 Hillemanns P, Friese K, Dannecker C. et al. Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) – Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia. Geburtshilfe Frauenheilkd 2019; 79: 148-159
• 36 Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004; 191: 105-113
• 37 Baldauf JJ, Dreyfus M, Ritter J. et al. Risk of cervical stenosis after large loop excision or laser conization. Obstet Gynecol 1996; 88: 933-938
• 38 Arbyn M, Ronco G, Anttila A. et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 Suppl 5: F88-F99
• 39 Griesser H, Marquardt K, Jordan B. et al. Münchner Nomenklatur III. Frauenarzt 2013; 11: 2-7
• 40 Girardi F, Frey Tirri B, Küppers V. et al. Neue kolposkopische IFCPC-Nomenklatur der Cervix uteri (Rio de Janeiro 2011). Frauenarzt 2012; 53: 1064-1066